

Access to Our HIV Medicines and the Patent Pool
27 April 2011

We share the goal of the Medicines Patent Pool Foundation (MPPF) to enhance access to medicines for HIV/AIDS. We are in regular contact with Ellen t'Hoën, the Executive Director of the MPPF. We met with her in April 2011, and expect to meet with her again to continue to discuss the pool's ability to handle a range of access issues.

Since 2004 we have been working on access throughout the world for all of our HIV medicines. We have entered into eight licensing agreements with low-cost generic manufacturers in sub-Saharan Africa and India. These agreements cover countries which are home to three out of every four people in the world living with HIV. Our access program makes no profit in these countries.

Four of these agreements are for darunavir and etravirine. For rilpivirine, our newest HIV medicine which we hope will begin to become available in certain countries this year, we have signed four agreements. We have also spoken with other generic companies about additional licenses. We believe our direct agreements with generic companies are working to provide access to these important medicines.